HR and breast cancer: In the current study, we focused on luminal-like breast cancer comprising the luminal-A and luminal-B subtypes, which are defined by the presence of hormonal receptor and absence of HER2 on the plasma membrane of tumor cells (i.e., HR+/HER2-) by the immunohistochemistry [10].